论文部分内容阅读
目的:观察在应用非洛地平的基础上加用氟伐他汀对糖耐量减低的高血压病患者超敏C反应蛋白(hs-CRP)及内皮功能的影响。方法:将符合纳入标准的高血压病并发糖耐量减低的患者127例随机分为2组:对照组(n=66)和氟伐他汀组(n=61),对照组服用非洛地平缓释片(10 mg,1次/d),氟伐他汀组在此基础上口服氟伐他汀(40 mg,1次/d),治疗12周。观察治疗前后患者hs-CRP和内皮功能等的变化。结果:经12周治疗后,两组hs-CRP[对照组:(2.9±1.5)mg/Lvs.(2.4±0.7)mg/L,P<0.05;氟伐他汀组:(2.9±1.5)mg/Lvs.(1.3±0.4)mg/L,P<0.01]、可溶性细胞间黏附分子-1(sICAM-1)[对照组:(114±47)μg/Lvs.(98±28)μg/L,P<0.05;氟伐他汀组:(118±46)μg/Lvs.(78±24)μg/ml,P<0.01]及可溶性血管细胞黏附分子-1(sVCAM-1)[对照组:(2 265±99)μg/Lvs.(190±56)μg/L,P<0.05;氟伐他汀组:(230±97)μg/Lvs.(158±36)μg/L,P<0.01]水平明显下降,与对照组相比氟伐他汀组hs-CRP及SICAM-1、SVCAM-1有更明显的降低,比较差异有统计学意义(均P<0.01)。结论:在应用非洛地平的基础上加用氟伐他汀能明显减低原发性高血压并发糖耐量减低患者hs-CRP的水平并改善患者的内皮功能。
AIM: To observe the effect of fluvastatin on hs-CRP and endothelial function in patients with impaired glucose tolerance (Hypertension). Methods: A total of 127 patients with concomitant hypertension and impaired glucose tolerance were randomly divided into two groups: control group (n = 66) and fluvastatin group (n = 61). The control group was treated with sustained release of felodipine The fluvastatin group was treated with fluvastatin (40 mg once daily) for 12 weeks. The changes of hs-CRP and endothelial function before and after treatment were observed. Results: After 12 weeks of treatment, the hs-CRP levels in the two groups were (2.9 ± 1.5) mg / L vs (2.4 ± 0.7) mg / /Lvs.(1.3 ± 0.4) mg / L, P <0.01], soluble intercellular adhesion molecule-1 (sICAM-1) (P <0.01) and soluble vascular cell adhesion molecule-1 (sVCAM-1) in the fluvastatin group: (118 ± 46) μg / Lvs 2 265 ± 99) μg / L vs 190 ± 56 μg / L, P <0.05; fluvastatin group: (230 ± 97) μg / L vs 158 ± 36 μg / L, P <0.01] (P <0.01). Compared with control group, hs-CRP, SICAM-1 and SVCAM-1 in fluvastatin group were significantly lower than those in control group (all P <0.01). Conclusion: The addition of fluvastatin to felodipine can significantly reduce the level of hs-CRP and improve endothelial function in patients with essential hypertension and impaired glucose tolerance.